Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of ruxolitinib topical cream for prurigo nodularis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Prurigo | Phase 3 | Status: COMPLETED | Results posted: 2025-11-14